Cargando…
Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design
The care for individuals with cystic fibrosis (CF) with at least one F508del mutation will greatly change as a result of the unparalleled clinical benefits observed with the new triple-combination CFTR (CF transmembrane regulator)–modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI). Incorporati...
Autores principales: | Mayer-Hamblett, Nicole, Nichols, David P., Odem-Davis, Katherine, Riekert, Kristin A., Sawicki, Greg S., Donaldson, Scott H., Ratjen, Felix, Konstan, Michael W., Simon, Noah, Rosenbluth, Daniel B., Retsch-Bogart, George, Clancy, John P., VanDalfsen, Jill M., Buckingham, Rachael, Gifford, Alex H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513667/ https://www.ncbi.nlm.nih.gov/pubmed/33465316 http://dx.doi.org/10.1513/AnnalsATS.202010-1336SD |
Ejemplares similares
-
The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network
por: Pearson, Kelsie, et al.
Publicado: (2021) -
The FOsmetpantotenate Replacement Therapy (FORT) randomized,
double-blind, Placebo-controlled pivotal trial: Study design and development
methodology of a novel primary efficacy outcome in patients with pantothenate
kinase-associated neurodegeneration
por: Klopstock, Thomas, et al.
Publicado: (2019) -
Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM‐HFpEF study
por: DiCarlo, Lorenzo A., et al.
Publicado: (2017) -
A point-of-care clinical trial comparing insulin administered using a
sliding scale versus a weight-based regimen
por: Fiore, Louis D, et al.
Publicado: (2011) -
Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
por: Reddy, K Rajender, et al.
Publicado: (2012)